Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of naronapride in idiopathic or diabetic gastroparesis
NL-OMON60472Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of naronapride in idiopathic gastroparesis (IG) and diabetic gastroparesis (2 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Change of the average weekly total symptom score. Started Sep 2023; status: completed.
02
Drugs
naronapride
03
Conditions
idiopathic gastroparesis (IG)diabetic gastroparesis
Beyond the preview
Go deeper on NL-OMON60472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60472.